Clinical Trial 23787

• Overview

  Study Title:

  A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors

  Summary:

  A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors.

  Objective:

  Primary Objectives: Phase 1a: - To evaluate the safety and tolerability of ALX2004 as a single agent in previously treated participants with known EGFR-expressing select advanced or metastatic solid tumors. - To determine the MTD at Q3W and Q2W and the recommended doses for expansion (RDEs) of ALX2004 as a single agent in previously treated participants with known EGFRexpressing select advanced or metastatic solid tumors. Phase 1b: - To further evaluate the preliminary response of ALX2004 as a single agent in previously treated participants with known EGFR-expressing select advanced or metastatic solid tumors. Secondary Objectives: Phase 1a: - To characterize the single and multiple-dose PK profiles of ALX2004 total antibody, total ADC, and TOP1 inhibitor payload. - To evaluate the immunogenicity of ALX2004. - To evaluate the preliminary anti-tumor activity of ALX2004 in previously treated participants with known EGFR-expressing select advanced or metastatic solid tumors. Phase 1b: - To further evaluate the preliminary additional anti-tumor activity of ALX2004 as a single agent in previously treated participants with known EGFR-expressing select advanced or metastatic solid tumors. - To further assess the overall safety and tolerability of ALX2004. - To further characterize the PK profiles of ALX2004. - To further evaluate the immunogenicity of ALX2004.

• Treatments

  Therapies:

  Antibody Drug Conjugate Targeting EGFR

  Medications:

  ALX2004 ()

• Inclusion Criteria

  Key Inclusion Criteria:
  • Participants with locally advanced, recurrent or metastatic histologically confirmed HNSCC, NSCLC, ESCC, CRC (left sided); locally advanced or recurrent disease must not be amenable to resection with curative intent.
  • Adequate Bone Marrow Function.
  • Adequate Renal & Liver Function.
  • Adequate Performance Status.
  • Additional criteria may apply.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Participants with disease suitable for local therapy with curative intent.
  • Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.
  • Prior treatment with any ADCs that have an active TOP1 inhibitor-based component.
  • Additional criteria may apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.